|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
BMI's Executive Summary[TOP] The Sector At A Glance Key Insights On The Pharmaceutical Sector Of Malaysia The Malaysian pharmaceutical market, which has expanded at an annual rate of around 8% in the past 12-18 months, has a relatively high growth potential when compared to other similarly developed countries in the region. Prescription drugs account for around 75% of the total market value, with the segment likely to remain dominant in the future due to private sector support for established prescribing habits. Branded drugs, which presently represent over 70% of the total market, will continue to command the larger share in terms of value, as the demand for novel and life-style drugs increases. The situation will be reflected in the rising share of imports over time, which will further tip the trade balance in favour of foreign-made products, especially as Malaysia finalises foreign trade agreements (FTA) with the US and other key trading partners. BMI expects the Malaysian pharmaceutical market to grow 12% in US dollar terms in 2006. Market value is likely to exceed US$1.56bn by 2010, boosted by changing demographics and rising healthcare expectations, which will boost demand for cardiovascular, central nervous system (CNS), metabolic and cancer drugs in particular. The treatment of infective diseases, especially hepatitis and HIV/AIDS, will necessitate supplies from abroad, while stimulating local R&D activities in this direction. However, the country’s continued failure to align its intellectual property (IP) regulations and enforcement with international standards will continue to hamper local activities of foreign companies, while simultaneously boosting the trade in fake drugs. Nevertheless, Malaysia will outperform a number of its immediate neighbours. The authorities’ commitment to the development of a local pharmaceutical R&D base will attract foreign investment. The demand for cheap generic medicines will remain strong, given that public hospitals – mostly supplied by a single government company – account for a significant share of the market. However, strong regional competition in the field of R&D, especially in biotechnology, will have some detrimental effect on the rate of industry expansion, as will the current deficiencies of the IP regime. Malaysian firms lack sufficient capacity to expand overseas, and will instead continue to focus on the local, mainly generic market. However, increased regional competition as well as the pressure on the authorities to comply with international IP standards will change the local landscape over the coming years, bringing a certain amount of industry consolidation. State-held Pharmanianga, the leading local player, will increase its efforts to secure a higher share of the generic market. In the meantime, multinational sector activity in the country will continue sporadically, dependent on prevailing regulatory and pricing conditions. |
||||||||||||||||
|
||||||||||||||||
Contents[TOP] Chapter 1 - Executive SummaryMalaysia Pharmaceuticals And Healthcare Industry SWOT Malaysia Political SWOT Malaysia Economic SWOT Malaysia Business Environment SWOT Chapter 2 - Malaysia: Business Environment RankingTable: Asia Business Environment Rankings Business Environment Ranking Economics – Long-Term Risk Politics – Long-Term Risk Regulatory Barriers Domestic Sector Threat Market Growth Potential Market Size Ranking Chapter 3 - Malaysia: Market SummaryChapter 4 - Regulatory RegimeForeign Co-Operation Recent Regulatory Developments Intellectual Property Regime Pricing And Reimbursement Industry Trends And Developments Healthcare Sector Table: HIV/AIDS Estimates (2003) Pharmaceutical Sector Table: Malaysia – Estimated Spending On Leading 40 Drugs, 2004 Pharmaceutical Demand Analysis Domestic Company Activity Foreign Company Developments Regional and Global Co-operation Biotechnology and Research Chapter 5 - Industry Forecast ScenarioOverall Market Forecast Table: Malaysian Drug Market Forecast Indicators Key Growth Factors – Industry Table: Malaysia – Health Expenditure Forecast Indicators Key Growth Factors – Macroeconomic Table: GDP, Population And Output Prescription Market Forecast Table: Malaysia – Prescription Drug Market Forecast Indicators OTC Market Forecast Table: Malaysia – OTC Market Forecast Indicators Generics and Branded Market Forecasts Table: Malaysia – Generics And Branded Drugs Market Forecast Indicators Export/Import Forecasts Table: Malaysia – Pharmaceuticals Exports And Imports Forecasts, US$ mn Other Healthcare Data Forecasts Table: Malaysia – Healthcare Data Forecasts Key Risks To BMI’s Forecast Scenario Chapter 6 - Competitive LandscapeTable: Malaysia – Estimated Spending On Leading 20 Drugs, 2004 Table: Leading Firms By 2005 Sales Chapter 7 - Company ProfilesGlaxoSmithKline Pfizer Novartis Merck & Co Sanofi-Aventis Ranbaxy Malaysia Eli Lilly Malaysia Leading Indigenous Manufacturers Pharmaniaga Asia Pharmaceutical Products Prime Pharmaceutical Bumimedic Hovid Chapter 8 - BMI Forecast ModellingHow We Generate Our Industry Forecasts Technical Process Pharmaceutical Industry Sources Chapter 9 - Appendix: Regional Demographic DataTable- Manufacturing Wages (ave per annum), US$ Table - Population Household Spending Per Capita, US$ Private Consumption Per Capita, US$ PPP Market Size, GDP, US$bn Chapter 10 - Country Snapshot: Malaysia Demographic DataSection 1: Population: Table: Demographic Indicators (2005) Table: Rural/Urban Breakdown Section 2: Education & Healthcare Table: Education Table: Healthcare: Vital Statistics Table: Healthcare: Expenditure Section 3: Labour Market And Spending Power Table: Employment Indicators Table: Consumption and Stratification Table: Wages per year
|
||||||||||||||||
|
||||||||||||||||
Competitive Landscape for Asia Pharmaceuticals and Healthcare: Sample of Companies Ranked[TOP] Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market. |
||||||||||||||||
Network of Asian Pharmaceuticals & Healthcare Sources[TOP] BMI's Asian Pharmaceuticals Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceuticals & healthcare industry associations, chambers of commerce and company reports. Information sources include: |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||